PSP Therapeutic Ideas

Migration, Crosslink

📖

PSP Therapeutic Ideas

active

wiki page Created: 2026-04-02T07:18:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-psp-therapeutic-ideas

📖 Wiki Page

treatment1864 wordssynced 2026-04-02

Path: /therapeutics/psp-therapeutic-ideas Title: PSP Therapeutic Ideas Tags: section:treatments, kind:treatment, disease:psp

<div class="infobox infobox-treatment">
<table>
<tr><th colspan="2" style="background:#e8f4f8;">Progressive Supranuclear Palsy Treatment</th></tr>
<tr><td><b>Disease</b></td><td>Progressive Supranuclear Palsy (PSP)</td></tr>
<tr><td><b>Pathology</b></td><td>4R-tauopathy, neurofibrillary tangles, tufted astrocytes</td></tr>
<tr><td><b>Subtypes</b></td><td>Richardson syndrome (classic), PSP-Parkinsonism, PSP-PAGF, Corticobasal syndrome</td></tr>
<tr><td><b>Key Targets</b></td><td>Tau protein, neuroinflammation, synaptic dysfunction</td></tr>
<tr><td><b>Treatment Focus</b></td><td>Disease-modifying, symptomatic, neuroprotective</td></tr>
</table>
</div>

Overview

Progressive Supranuclear Palsy (PSP), also known as Steele-Richardson-Olszewski syndrome, is a rare, rapidly progressive neurodegenerative disorder classified as a 4R-tauopathy[@steele1964]. Unlike [Parkinson's disease](/diseases/parkinsons-disease), PSP shows minimal and transient response to dopaminergic medications, and disease progression is more rapid with a median survival of 6-9 years from symptom onset. Current therapeutic approaches focus on symptomatic management of motor, ocular, and cognitive symptoms, with emerging disease-modifying therapies targeting the underlying tau pathology.

Disease-Modifying Therapies

Tau-Targeted Approaches

Immunotherapies

...

Path: /therapeutics/psp-therapeutic-ideas Title: PSP Therapeutic Ideas Tags: section:treatments, kind:treatment, disease:psp

<div class="infobox infobox-treatment">
<table>
<tr><th colspan="2" style="background:#e8f4f8;">Progressive Supranuclear Palsy Treatment</th></tr>
<tr><td><b>Disease</b></td><td>Progressive Supranuclear Palsy (PSP)</td></tr>
<tr><td><b>Pathology</b></td><td>4R-tauopathy, neurofibrillary tangles, tufted astrocytes</td></tr>
<tr><td><b>Subtypes</b></td><td>Richardson syndrome (classic), PSP-Parkinsonism, PSP-PAGF, Corticobasal syndrome</td></tr>
<tr><td><b>Key Targets</b></td><td>Tau protein, neuroinflammation, synaptic dysfunction</td></tr>
<tr><td><b>Treatment Focus</b></td><td>Disease-modifying, symptomatic, neuroprotective</td></tr>
</table>
</div>

Overview

Progressive Supranuclear Palsy (PSP), also known as Steele-Richardson-Olszewski syndrome, is a rare, rapidly progressive neurodegenerative disorder classified as a 4R-tauopathy[@steele1964]. Unlike [Parkinson's disease](/diseases/parkinsons-disease), PSP shows minimal and transient response to dopaminergic medications, and disease progression is more rapid with a median survival of 6-9 years from symptom onset. Current therapeutic approaches focus on symptomatic management of motor, ocular, and cognitive symptoms, with emerging disease-modifying therapies targeting the underlying tau pathology.

Disease-Modifying Therapies

Tau-Targeted Approaches

Immunotherapies

Tau immunotherapy aims to reduce extracellular tau propagation and enhance clearance of toxic aggregates:

Anti-tau antibodies: Several monoclonal antibodies targeting different tau epitopes are in development
Lunemastemab (ABBV-8E12): Anti-tau antibody targeting aggregated tau; completed Phase 2 trials for PSP[@budur2019]
Gantenerumab: Anti-[Aβ](/proteins/amyloid-beta)/tau bispecific antibody; being evaluated in tauopathies[@ostrowitzki2011]
Tilavonemab (ABBV-8E12): Showed biomarker engagement but did not meet primary endpoints in PSP[@florian2021]

Tau Aggregation Inhibitors

Small molecules designed to prevent or reverse tau aggregation:

Methylene blue derivatives: Include TRx0237 (LMTX), which showed mixed results in Phase 3 trials for AD and is being evaluated for PSP[@wischik2015]
Phenylthiazolyl-hydrazide compounds: Preclinical candidates targeting tau oligomerization[@taniguchi2005]
Epigallocatechin gallate (EGCG): Natural compound with anti-aggregation properties; limited clinical data in PSP[@xu2002]

Tau Kinase Inhibitors

Targeting enzymes responsible for tau hyperphosphorylation:

[GSK-3β](/entities/gsk3-beta) inhibitors: Lithium and other GSK-3β inhibitors have shown tau phosphorylation reduction in preclinical models[@engel2006]
[CDK5](/proteins/cdk5) inhibitors: Being explored to prevent pathological tau phosphorylation[@zheng2005]

Neuroprotective Strategies

NRF2 Activators

Targeting oxidative stress pathways:

Sulforaphane: Increases expression of antioxidant response genes; preclinical evidence supports neuroprotection in tauopathies[@deng2020]
Dimethyl fumarate (Tecfidera): FDA-approved for MS, being investigated for neuroprotection in PSP

Mitochondrial Support

Coenzyme Q10: Supports mitochondrial electron transport; small trials showed modest benefit in PSP[@stamelou2008]
Mitochondrial peptides (SS-31): Targeting mitochondrial dysfunction; being evaluated in neurodegenerative diseases[@wu2016]

Neuroinflammation Modulation

TNF-α inhibitors: Etanercept and other anti-TNF approaches being explored[@tobinick2009]
Microglial modulation: Targeting CD33, [TREM2](/proteins/trem2) pathways to modify microglial response[@griciuc2021]

Symptomatic Treatment

Motor Symptoms

Dopaminergic Therapy

Response in PSP is typically poor and short-lived:

Levodopa: Modest benefit in some patients with PSP-Parkinsonism subtype; doses up to 1000-2000 mg/day may be tried[@kompoliti1998]
Dopamine agonists: Pramipexole, ropinirole may provide limited benefit
Expected response: Only 20-30% show meaningful improvement, benefits often diminish within months

Management of Rigidity and Dystonia

Botulinum toxin injections: For cervical dystonia, blepharospasm[@truong2006]
Muscle relaxants: Baclofen, tizanidine for spasticity
Physical therapy: Essential for maintaining mobility and preventing contractures

Ocular Motility Issues

Vertical Supranuclear Gaze Palsy

Prism lenses: May help compensate for gaze limitations
Environmental modifications: Adjust lighting, reading position
Speech/occupational therapy: Strategies for coping with visual limitations

Blepharospasm

Botulinum toxin injections: First-line treatment[@hallett2004]
Blepharoplasty: Surgical option for severe cases

Cognitive and Behavioral Symptoms

Executive Dysfunction

[Cholinesterase inhibitors](/entities/cholinesterase-inhibitors): Modest benefit in some patients ([donepezil](/entities/donepezil), rivastigmine)[@liepelt2010]
Stimulants: Methylphenidate may help with apathy
Behavioral interventions: Structured routines, environmental modifications

Pseudobulbar Affect

Dextromethorphan/quinidine (Nuedexta): FDA-approved for pseudobulbar affect; effective in PSP[@schrag2010]
Alternative: Amitriptyline may provide some benefit

Sleep Disorders

REM sleep behavior disorder: Melatonin, clonazepam
Insomnia: Sleep hygiene, sedating medications (use cautiously)
Sleep-disordered breathing: CPAP/BiPAP as needed

Clinical Trials Landscape

Active and Recent Trials

| Agent | Mechanism | Phase | Status |
|-------|-----------|-------|--------|
| Gantenerumab | Anti-tau antibody | 2 | Completed |
| Tilavonemab (ABBV-8E12) | Anti-tau antibody | 2 | Completed |
| Lunemastemab (ABBV-8E12) | Anti-tau antibody | 2 | Completed |
| TRx0237 (LMTX) | Tau aggregation inhibitor | 3 | Completed |
| Sodium selenate | Tau dephosphorylation | 2 | Completed |
| Davunetide | Microtubule stabilizer | 3 | Completed |
| Lithium | GSK-3β inhibitor | 2 | Completed |
| Coenzyme Q10 | Mitochondrial support | 2 | Completed |

Challenges in PSP Clinical Trials

Rapid progression: Short window for intervention
Diagnostic accuracy: Early PSP difficult to distinguish from PD
Heterogeneity: Multiple clinical subtypes have different trajectories
Floor effect: Patients often too advanced at diagnosis
Outcome measures: Lack of validated sensitive biomarkers
Tau burden: Significant pathology already present at clinical onset

Emerging and Investigational Approaches

Gene Therapy

AAV-based delivery: Targeting neurotrophic factors (GDNF, NTF3)[@tarditi2022]
Tau gene silencing: ASO and siRNA approaches targeting [MAPT](/proteins/tau) mRNA
Gene editing: CRISPR-based approaches (preclinical)

Cell-Based Therapies

Mesenchymal stem cells: Being explored for neuroprotection and immunomodulation[@tsai2018]
Neural stem cell transplantation: Investigational for replacing lost [neurons](/entities/neurons)

Biomarker Development

Critical need for biomarkers to enable earlier diagnosis and monitor treatment response:

[Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL): Promising blood biomarker for disease progression and treatment response[@bckstrm2016]
Tau PET imaging: Pittsburgh compound B and novel tau ligands for tracking tau burden
CSF tau species: Total tau, phosphorylated tau, tau oligomers

Novel Targets

Synaptic dysfunction: Synaptic vesicle proteins, [NMDA receptor](/entities/nmda-receptor) modulators
Epigenetic modifications: [HDAC](/entities/hdac-enzymes) inhibitors, [DNA methylation](/entities/dna-methylation) modulators
[Autophagy](/entities/autophagy) enhancers: Rapamycin, trehalose for promoting protein clearance

Non-Pharmacological Approaches

Physical Therapy

Gait and balance training: Fall prevention strategies[@morris2009]
Strength training: Maintain muscle mass and function
Aquatic therapy: Reduced fall risk during exercise
Assistive devices: Canes, walkers as disease progresses

Occupational Therapy

Home modifications: Safety adaptations, grab bars
Energy conservation techniques
Adaptive equipment: For eating, dressing, writing
Visual compensation strategies

Speech Therapy

Dysphagia management: Swallowing techniques, dietary modifications[@langmore2002]
Speech therapy: For dysarthria management
Communication devices: As disease progresses

Fall Prevention

Home safety assessment: Remove tripping hazards
Footwear recommendations: Proper shoes
Vision correction: Regular eye exams
Medication review: Minimize sedating medications

Prognosis and Treatment Goals

PSP has a median survival of 6-9 years from symptom onset, with more rapid progression than Parkinson's disease[@wenning2013]. Treatment goals focus on:

Maximizing functional independence through optimal symptom management

Preventing complications (falls, aspiration, pressure ulcers)

Maintaining quality of life through comprehensive supportive care

Managing expectations with realistic goal-setting

Participating in clinical trials to contribute to advancing knowledge

Cross-References

[Steele-Richardson-Olszewski Syndrome (PSP Overview)](/diseases/steele-richardson-olszewski-syndrome)
[Tau Protein](/proteins/tau)
[MAPT Gene](/genes/mapt)
[4R-Tauopathies](/mechanisms/4r-tauopathy-mechanisms)
[Corticobasal Syndrome](/diseases/corticobasal-syndrome)
[Parkinson's Disease Treatment](/therapeutics/parkinson-treatment)
[Tau Immunotherapy](/therapeutics/tau-immunotherapy)
[Multiple System Atrophy](/diseases/multiple-system-atrophy)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy

References

[Steele JC, Richardson JC, Olszewski J, Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia (1964)](https://pubmed.ncbi.nlm.nih.gov/14124698/)

[Budur K, Kumar S, Guss J, et al, Efficacy and safety of ABBV-8E12 in progressive supranuclear palsy (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.08.015)

[Ostrowitzki S, Deptula D, Thurfjell L, et al, Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab (2011)](https://doi.org/10.1001/archneurpsyc.2011.1538)

[Florian H, Wang D, Arnold SE, et al, Tilavonemab for the treatment of progressive supranuclear palsy (2021)](https://doi.org/10.1016/j.trci.2021.03.002)

[Wischik CM, Staff RT, Akaida T, et al, Tau aggregation inhibitor therapy: an exploration of efficacy and disease modification in Alzheimer's disease and primary tauopathies (2015)](https://doi.org/10.1186/s13195-015-0141-9)

[Taniguchi S, Suzuki N, Masuda M, et al, Phenylthiazolylhydrazide derivatives as inhibitors of tau fibril formation (2005)](https://doi.org/10.1074/jbc.M503461200)

[Xu J, Kao SY, Lee FJ, et al, Dopamine-dependent neurotoxicity induced by MPTP is attenuated by green tea polyphenol (-)-epigallocatechin-3-gallate (2002)](https://pubmed.ncbi.nlm.nih.gov/11980873/)

[Engel T, Goñi-Oliver P, Lucas JJ, et al, Chronic lithium administration to FTDP-17 tau and GSK-3β overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert (2006)](https://doi.org/10.1111/j.1471-4159.2006.04139.x)

[Zheng YL, Kesavapany S, Gravell M, et al, A CDK5-derived peptide inhibits Cdk5/p25 activity and improves neuronal viability in oxidatively stressed cultured neurons (2005)](https://doi.org/10.1523/JNEUROSCI.25-30-07656.2005)

[Deng G, Wang J, Liu W, et al, Sulforaphane exerts neuroprotective effects via Nrf2/HO-1 signaling in a rat model of Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/33125670/)

[Stamelou M, Reuss A, Pilatus U, et al, Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial (2008)](https://doi.org/10.1016/j.jad.2008.02.016)

[Wu HY, Tang EK, Lin CY, et Szeto PP, Mitochondria-targeted peptide SS-31 attenuates neuronal injury via mitochondrial protective effect after spinal cord injury (2016)](https://doi.org/10.1111/neuros.13533)

[Tobinick EL, Perispinal etanercept for neuroinflammatory disorders (2009)](https://doi.org/10.1016/j.drudis.2009.01.025)

[Griciuc A, Tanzi RE, The role of microglial TREM2 and AD risk genes in Alzheimer's disease (2021)](https://doi.org/10.1016/j.neuron.2021.02.010)

[Kompoliti K, Goetz CG, Litvan I, et al, Pharmacological therapy in progressive supranuclear palsy (1998)](https://pubmed.ncbi.nlm.nih.gov/9819023/)

[Truong DD, Bhidayasiri R, Botulinum toxin therapy for cervical dystonia in progressive supranuclear palsy (2006)](https://pubmed.ncbi.nlm.nih.gov/17106791/)

[Hallett M, Eidelman O, Walz B, et al, Botulinum toxin for blepharospasm and hemifacial spasm (2004)](https://doi.org/10.1016/j.pmr.2004.08.009)

[Liepelt I, Gaenslen A, Godau J, et al, Rivastigmine for the treatment of dementia in progressive supranuclear palsy (2010)](https://pubmed.ncbi.nlm.nih.gov/20206395/)

[Schrag A, Sheikh S, Quinn NP, et al, A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy (2010)](https://doi.org/10.1002/mds.23455)

[Tarditi M, Caricasole A, Marconi R, Gene therapy for neurodegenerative diseases: the role of AAV vectors (2022)](https://pubmed.ncbi.nlm.nih.gov/35247812/)

[Tsai CP, Lee JK, Lee CT, Mesenchymal stem cells in the treatment of neurodegenerative disorders (2018)](https://pubmed.ncbi.nlm.nih.gov/29610926/)

[Bäckström DC, Eriksson Domellöf M, Zetterberg H, et al, Neurofilament light chain in cerebrospinal fluid and prediction of progression in patients with prodromal and manifest Alzheimer's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/26757275/)

[Morris ME, Iansek R, Kirkwood B, A randomized controlled trial of movement strategies compared with exercise for people with Parkinson's disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19127577/)

[Langmore SE, Terpenning MS, Schatz A, et al, Predictors of aspiration pneumonia: how important is dysphagia? (2002)](https://pubmed.ncbi.nlm.nih.gov/11891904/)

[Wenning GK, Geser F, Krismer F, et al, The natural history of multiple system atrophy: a prospective European cohort study (2013)](https://doi.org/10.1016/S1474-4422(13)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
[Astrocyte-Mediated Neuronal Epigenetic Rescue](/hypothesis/h-8fe389e8) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: HDAC
[APOE-TREM2 Interaction Modulation](/hypothesis/h-180807e5) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: TREM2
[TREM2-Mediated Selective Aggregate Clearance Pathway](/hypothesis/h-3460f820) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: TREM2
[TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: TREM2
[TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TREM2
[Designer TRAK1-KIF5 fusion proteins accelerate therapeutic mitochondrial delivery](/hypothesis/h-346639e8) — <span style="color:#ffd54f;font-weight:600">0.48</span> · Target: TRAK1_KIF5A

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
[Protein aggregation cross-seeding across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-9137255b) 🔄
[Mechanistic role of APOE in neurodegeneration](/analysis/SDA-2026-04-01-gap-auto-fd6b1635d9) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-psp-therapeutic-ideas

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-psp-therapeutic-ideas
kg_node_id	None
entity_type	treatment
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-6ffe4577d933
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-psp-therapeutic-ideas'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

55

Outgoing

94

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

PSP Therapeutic Ideas

Overview

Disease-Modifying Therapies

Tau-Targeted Approaches

Immunotherapies

Overview

Disease-Modifying Therapies

Tau-Targeted Approaches

Immunotherapies

Tau Aggregation Inhibitors

Tau Kinase Inhibitors

Neuroprotective Strategies

NRF2 Activators

Mitochondrial Support

Neuroinflammation Modulation

Symptomatic Treatment

Motor Symptoms

Dopaminergic Therapy

Management of Rigidity and Dystonia

Ocular Motility Issues

Vertical Supranuclear Gaze Palsy

Blepharospasm

Cognitive and Behavioral Symptoms

Executive Dysfunction

Pseudobulbar Affect

Sleep Disorders

Clinical Trials Landscape

Active and Recent Trials

Challenges in PSP Clinical Trials

Emerging and Investigational Approaches

Gene Therapy

Cell-Based Therapies

Biomarker Development

Novel Targets

Non-Pharmacological Approaches

Physical Therapy

Occupational Therapy

Speech Therapy

Fall Prevention

Prognosis and Treatment Goals

Cross-References

See Also

External Links

Allen Brain Atlas Resources

References

Related Hypotheses

💬 Discussion